Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
31.18
+0.02 (0.06%)
At close: May 15, 2026, 4:00 PM EDT
31.05
-0.13 (-0.42%)
After-hours: May 15, 2026, 7:44 PM EDT
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Catalyst Pharmaceuticals stock has a target of 31.5, which predicts a 1.03% increase from the current stock price of 31.18.
Price Target: $31.5 (+1.03%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Catalyst Pharmaceuticals stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy → Hold Downgrades $35 → $32 | Strong Buy → Hold | Downgrades | $35 → $32 | +1.03% | May 8, 2026 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | May 7, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $33 → $35 | Strong Buy | Maintains | $33 → $35 | +12.25% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $31 → $33 | Strong Buy | Maintains | $31 → $33 | +5.84% | Nov 7, 2025 |
| Baird | Baird | Buy Maintains $28 → $32 | Buy | Maintains | $28 → $32 | +2.63% | Mar 3, 2025 |
Financial Forecast
Revenue This Year
643.79M
from 588.99M
Increased by 9.30%
Revenue Next Year
712.84M
from 643.79M
Increased by 10.73%
EPS This Year
2.06
from 1.68
Increased by 22.89%
EPS Next Year
2.34
from 2.06
Increased by 13.44%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 676.1M | 764.3M | ||||||
| Avg | 643.8M | 712.8M | ||||||
| Low | 608.6M | 620.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 14.8% | 18.7% | ||||||
| Avg | 9.3% | 10.7% | ||||||
| Low | 3.3% | -3.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.90 | 3.50 | |||
| Avg | 2.06 | 2.34 | |||
| Low | 1.71 | 1.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 72.5% | 69.4% | |||
| Avg | 22.9% | 13.4% | |||
| Low | 1.5% | -17.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.